64,666
Participants
Start Date
September 25, 2017
Primary Completion Date
September 30, 2020
Study Completion Date
December 31, 2021
Early Patient-Level and Provider-Level Educational Intervention
"Letters to patients that (1) explain to the patient that he or she appears to have AF, characterize the risk of stroke, and emphasize that although there may be a medical reason, the patient does not seem to be on an anticoagulant and (2) encourage the patient to discuss this with his or her provider to ask if he or she might benefit from OAC therapy to prevent stroke.~Early intervention letters to providers explain this project, the nature of the problem, and identify a list of the provider's patients who have been contacted, as the provider and patient letters will be sent at approximately the same time; describe evidence and guidelines regarding oral anticoagulation."
Delayed Provider-Level Educational Intervention
Delayed intervention letters to patients' providers, where they may be identified, that explain this project, the nature of the problem, and identify a list of their patients who are flagged as at risk for stroke and have not been treated with an oral anticoagulant; describe evidence and guidelines regarding oral anticoagulation.
Aetna, Inc., Blue Bell
Humana Healthcare Research, Inc., Louisville
Harvard Pilgrim Health Care, Quincy
OptumInsight, Inc, Waltham
Collaborators (2)
Duke Clinical Research Institute
OTHER
Clinical Trials Transformation Initiative
OTHER
Humana Inc.
INDUSTRY
Aetna, Inc.
INDUSTRY
OptumInsight Life Sciences, Inc.
UNKNOWN
Food and Drug Administration (FDA)
FED
Harvard Pilgrim Health Care
OTHER